Estratab (.3 mg )
Company: Solvay PharmaceuticalsApproval Status: Approved March 1998
Treatment for: prevention of osteoporosis
Areas: Diabetes / Endocrinology; Musculoskeletal; Pregnancy & Gynecology
| General Information | Clinical Results | Side Effects |
General Information
Estratab (.3 mg ) has been approved for the prevention of osteoporosis.
Clinical Results
In a two-year clinical trial, women on .3 mg Estratab tablets showed increased bone mineral density over baseline in the spine, hip, and whole body.
Side Effects
Women taking this low dose also experienced fewer side effects, such as headache, nausea, breast tenderness, and vaginal bleeding, than women on higher doses.
Estratab Drug Information
The Estratab drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
